tradmap

ARTV Artiva Biotherapeutics, Inc.

$11.14 -1.76%

Updated

Healthcare · Biological Products, (No Diagnostic Substances)

Artiva Biotherapeutics, Inc. (ARTV) is a healthcare company in the Biological Products, (No Diagnostic Substances) industry, with a market capitalization of $545 million. Shares last traded at $11.14, 30.0% below their 52-week high. Over the past year the stock is up 251.4%. Revenue declined 100.0% year over year.

Market Cap
$545M
Shares Out
48.9M
EPS (TTM)
$-6.76
P/E Ratio
P/S Ratio
P/B Ratio
1.57
Dividend / Share
Dividend Yield
52-Week High
$15.91
52-Week Low
$2.24
Volume
13,340
Avg Vol (3m)
20,125.492

Performance

1W
-6.66%
1M
-3.38%
3M
+45.81%
6M
+97.17%
YTD
+159.07%
1Y
+251.42%

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
50.20
SMA (50)
$10.53
SMA (200)
$7.39
Price vs SMA50
+5.81%
Price vs SMA200
+50.83%
ATR (14)
$0.63

Full technical analysis (26 indicators, D/W/M) →

Financials

Revenue
$0M
Net Income
$-91M
Gross Margin
Operating Margin
Net Margin
Return on Equity
-26.1%
Return on Assets
-24.6%
Current Ratio
24.16
Debt / Equity
0.06
Revenue Growth (YoY)
-100.0%

Latest reported annual period ending 2026-06-30 · SEC EDGAR/XBRL.

Full financials — revenue, cash flow & debt over time →

Recent earnings

PeriodEPS (diluted)Reported
Q2 2026 $-1.51 2026-08-06
Q1 2026 $-0.95 2026-05-08
FY 2025 $-3.43 2026-03-10
Q3 2025 $-2.59 2025-11-12
Q2 2026 $-1.71 2026-08-06
Q1 2026 $-0.83 2026-05-08

Full earnings history →

Biological Products, (No Diagnostic Substances) peers

ARTV vs 14 industry peers (Biological Products, (No Diagnostic Substances)), by market cap. Updated

1–14 of 14
AMGNAmgen$240.1B27.476.3023.0%+0.31%
GILDGilead Sciences$187.5B-57.876.16-10.6%+1.09%
MRNAModerna$58.8B-18.68-1.94%
RVMDRevolution Medicines, Inc.$45.2B-25.55+0.76%
BIIBBiogen$33.1B24.163.3413.8%+0.78%
NBIXNeurocrine Biosciences Inc$16.1B22.814.7720.9%+0.33%
EXELExelixis, Inc.$14.7B17.036.0235.3%+1.00%
HALOHalozyme Therapeutics, Inc.$12.6B30.397.5524.9%+1.01%
TECHBio-Techne$11.4B62.489.3515.0%+0.21%
KRYSKrystal Biotech, Inc.$11.0B45.5224.9554.8%+0.58%
APGEApogee Therapeutics, Inc.$10.2B-34.57+0.04%
KYMRKymera Therapeutics, Inc.$9.7B-32.51-1.24%
RGENRepligen Corp$9.6B230.5312.205.3%-1.87%
PCVXVaxcyte, Inc.$9.1B-8.56-0.62%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.